Sobha Sivaprasad

Summary

Affiliation: Moorfields Eye Hospital
Country: UK

Publications

  1. doi request reprint What is new in the management of wet age-related macular degeneration?
    Sobha Sivaprasad
    Moorfields Eye Hospital, 162 City Road, London, UK
    Br Med Bull 105:201-11. 2013
  2. doi request reprint Contrast sensitivity outcomes in the ABC Trial: a randomized trial of bevacizumab for neovascular age-related macular degeneration
    Praveen J Patel
    NIHR Biomedical Research Centre for Ophthalmology, Moorfields Eye Hospital and UCL Institute of Ophthalmology, London, UK
    Invest Ophthalmol Vis Sci 52:3089-93. 2011
  3. doi request reprint Visual acuity outcomes in ranibizumab-treated neovascular age-related macular degeneration; stratified by baseline vision
    Olajumoke Shona
    King s College Hospital, Denmark Hill, London, UK
    Clin Experiment Ophthalmol 39:5-8. 2011
  4. pmc Structural and functional measures of efficacy in response to bevacizumab monotherapy in diabetic macular oedema: exploratory analyses of the BOLT study (report 4)
    Sobha Sivaprasad
    NIHR Moorfields Biomedical Research Centre, Moorfields Eye Hospital, London, United Kingdom
    PLoS ONE 8:e72755. 2013
  5. doi request reprint Injection frequency and response to bevacizumab monotherapy for diabetic macular oedema (BOLT Report 5)
    Sobha Sivaprasad
    NIHR Biomedical Research Centre for Ophthalmology, Moorfields Eye Hospital, London, UK
    Br J Ophthalmol 97:1177-80. 2013
  6. doi request reprint Agreement between time-domain and spectral-domain optical coherence tomography in the assessment of macular thickness in patients with idiopathic macular telangiectasia type 2
    Raeba Mathew
    NIHR Biomedical Research Centre for Ophthalmology, Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology, London, UK
    Ophthalmologica 230:144-50. 2013
  7. doi request reprint Prevalence of diabetic retinopathy in various ethnic groups: a worldwide perspective
    Sobha Sivaprasad
    King s College Hospital NHS Foundation Trust, Denmark Hill, London, UK
    Surv Ophthalmol 57:347-70. 2012
  8. doi request reprint Subthreshold diode laser micropulse photocoagulation for the treatment of diabetic macular edema
    Sobha Sivaprasad
    King s College Hospital, Laser and Retinal Research Unit, Denmark Hill, London, SE5 9RS, UK
    Expert Rev Med Devices 9:189-97. 2012
  9. ncbi request reprint Hypoxia and oxidative stress in the causation of diabetic retinopathy
    Geoffrey B Arden
    Henry Wellcome Research Laboratories, Centre for Applied Vision Sciences, Department of Optometry and Visual Science, School of Community and Health Sciences, City University, Northampton Square, London, UK
    Curr Diabetes Rev 7:291-304. 2011
  10. doi request reprint Treatment of proliferative diabetic retinopathy with anti-VEGF agents
    Aysha Salam
    Laser and Retinal Research Unit, Department of Ophthalmology, King s College Hospital NHS Foundation Trust, Denmark Hill, London, UK
    Acta Ophthalmol 89:405-11. 2011

Collaborators

  • Tunde Peto
  • Giorgio Dorin
  • Michel Michaelides
  • Raeba Mathew
  • Geoffrey B Arden
  • Waheeda Rahman
  • Noel Horgan
  • Fred K Chen
  • Quresh Mohamed
  • Bhaskar Gupta
  • Praveen J Patel
  • Aysha Salam
  • Olajumoke Shona
  • Richard Seebaran
  • Kanom Bibi
  • Mohammed Musadiq
  • Wen Xing
  • Graham Brown
  • Nicola Duff
  • Marion Campbell
  • Rebecca Black
  • Roopa Vemala
  • Zdenek Gregor
  • Clare Bailey
  • Liam Patton
  • Mohammed Majid
  • Gayatri Banerjee
  • Astrid Fletcher
  • Yvonne D'Souza
  • Jonathan Dowler
  • Jagdev Bains
  • Matthew Richardson
  • Andrew Browning
  • Philip Hykin
  • Alison Murphy
  • Sam Fraser-Bell
  • Tariq Aslam
  • Richard Hanson
  • Maria Niskopolou
  • Catherine Grigg
  • Ola Segun-Odumosu
  • Jen Smith
  • Lyndon da Cruz
  • Rajen Gupta
  • Dan Ehrlich
  • Tryfon Rotsos
  • Laura Henderson
  • Catey Bunce
  • Robert Johnston
  • Sonal Rughani
  • Nachi Acharya
  • Shima Shah
  • Adnan Tufail
  • Andrew Kaines
  • Richard Poynter
  • Gary S Rubin
  • Kerry Waller
  • Richard Wormald
  • Catherine Egan
  • Robyn Guymer
  • Kulwant Sehmi
  • Frank Holz
  • Praveen Patel
  • Mina Devani
  • Felicia Ikeji
  • Sreedhar Jyothi

Detail Information

Publications12

  1. doi request reprint What is new in the management of wet age-related macular degeneration?
    Sobha Sivaprasad
    Moorfields Eye Hospital, 162 City Road, London, UK
    Br Med Bull 105:201-11. 2013
    ..The key cytokine involved in the pathogenesis of CNV is vascular endothelial growth factor (VEGF). Since 2005, antiVEGF therapy has revolutionized the management of this condition...
  2. doi request reprint Contrast sensitivity outcomes in the ABC Trial: a randomized trial of bevacizumab for neovascular age-related macular degeneration
    Praveen J Patel
    NIHR Biomedical Research Centre for Ophthalmology, Moorfields Eye Hospital and UCL Institute of Ophthalmology, London, UK
    Invest Ophthalmol Vis Sci 52:3089-93. 2011
    ..To report the impact of intravitreous bevacizumab therapy on contrast sensitivity in patients with neovascular age-related macular degeneration (nAMD)...
  3. doi request reprint Visual acuity outcomes in ranibizumab-treated neovascular age-related macular degeneration; stratified by baseline vision
    Olajumoke Shona
    King s College Hospital, Denmark Hill, London, UK
    Clin Experiment Ophthalmol 39:5-8. 2011
    ..This study assessed the real-life outcomes based on baseline visual acuity when treated with intravitreal ranibizumab on a three + pro re nata (PRN) dosing schedule for NVAMD...
  4. pmc Structural and functional measures of efficacy in response to bevacizumab monotherapy in diabetic macular oedema: exploratory analyses of the BOLT study (report 4)
    Sobha Sivaprasad
    NIHR Moorfields Biomedical Research Centre, Moorfields Eye Hospital, London, United Kingdom
    PLoS ONE 8:e72755. 2013
    ..To describe structural and functional changes associated with diabetic macular oedema (DMO) treated with intravitreal bevacizumab over 24 months...
  5. doi request reprint Injection frequency and response to bevacizumab monotherapy for diabetic macular oedema (BOLT Report 5)
    Sobha Sivaprasad
    NIHR Biomedical Research Centre for Ophthalmology, Moorfields Eye Hospital, London, UK
    Br J Ophthalmol 97:1177-80. 2013
    ..To explore the parameters that influence injection frequency in patients treated with intravitreal bevacizumab (ivB) for diabetic macular oedema. Injection frequency was considered as a surrogate marker of persistent or recurrent oedema...
  6. doi request reprint Agreement between time-domain and spectral-domain optical coherence tomography in the assessment of macular thickness in patients with idiopathic macular telangiectasia type 2
    Raeba Mathew
    NIHR Biomedical Research Centre for Ophthalmology, Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology, London, UK
    Ophthalmologica 230:144-50. 2013
    ..To estimate the conversion factors to transpose macular thickness measurements on time-domain (TD) to various spectral-domain (SD) optical coherence tomography (OCT) machines in patients with macular telangiectasia type 2a (MacTel)...
  7. doi request reprint Prevalence of diabetic retinopathy in various ethnic groups: a worldwide perspective
    Sobha Sivaprasad
    King s College Hospital NHS Foundation Trust, Denmark Hill, London, UK
    Surv Ophthalmol 57:347-70. 2012
    ..We examine the ethnicity and region-based prevalence of diabetic retinopathy around the world and highlight the need to reinforce ethnicity-based screening and treatment thresholds in diabetic retinopathy...
  8. doi request reprint Subthreshold diode laser micropulse photocoagulation for the treatment of diabetic macular edema
    Sobha Sivaprasad
    King s College Hospital, Laser and Retinal Research Unit, Denmark Hill, London, SE5 9RS, UK
    Expert Rev Med Devices 9:189-97. 2012
    ..This review describes the principles of subthreshold diode laser micropulse photocoagulation, its treatment modalities and clinical outcomes in the context of standard laser treatments and of emerging nonlaser therapies for DME...
  9. ncbi request reprint Hypoxia and oxidative stress in the causation of diabetic retinopathy
    Geoffrey B Arden
    Henry Wellcome Research Laboratories, Centre for Applied Vision Sciences, Department of Optometry and Visual Science, School of Community and Health Sciences, City University, Northampton Square, London, UK
    Curr Diabetes Rev 7:291-304. 2011
    ..If oxidative stress is considered 'the' determinant of DR, explanation of such findings solely in terms of oxidative stress would require additional hypotheses...
  10. doi request reprint Treatment of proliferative diabetic retinopathy with anti-VEGF agents
    Aysha Salam
    Laser and Retinal Research Unit, Department of Ophthalmology, King s College Hospital NHS Foundation Trust, Denmark Hill, London, UK
    Acta Ophthalmol 89:405-11. 2011
    ..This review analyses published studies using anti-VEGF agents alone or as an adjunct to other therapies in the treatment of PDR...
  11. doi request reprint Current treatment options for retinal angiomatous proliferans (RAP)
    Bhaskar Gupta
    Ophthalmology Department, King s College Hospital, London, UK
    Br J Ophthalmol 94:672-7. 2010
    ..This review of current literature on RAP compares the outcomes of various treatment options for this condition and highlights the lack of clinical trials and paucity of long-term data on this relatively common condition...
  12. doi request reprint Micropulsed diode laser therapy: evolution and clinical applications
    Sobha Sivaprasad
    Department of Ophthalmology, King s College Hospital, London, UK
    Surv Ophthalmol 55:516-30. 2010
    ..The report includes the rationale and basic principles underlying micropulse diode laser therapy, together with a review of its current clinical applications...